Activist hedge fund Starboard Value's chief executive officer said on Tuesday that drugmaker Pfizer's board needs to hold ...

Starboard's Jeff Smith told Pfizer in a meeting last week that they need to improve their return on investments in R&D and ...

Jeff Smith, Starboard Value CEO, joins CNBC's 'Squawk on the Street' to discuss how he sees Pfizer going forward, potential ...

Starboard has a $1 billion stake in Pfizer and an unknown but "sizable" stake in Kenvue, according to earlier media reports.

Starboard Value criticizes Pfizer's leadership for underperformance, citing a 50% stock decline and missed growth targets ...

Despite that cash windfall, Pfizer has "dramatically underperformed its peers and the market since 2019," according to ...

Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job.

Pfizer (PFE) faces renewed calls for change as Jeffrey Smith, CEO of Starboard Value makes his case for his activist stance ...

Activist hedge fund Starboard Value believes the root cause of Pfizer’s issues are the low expected returns on its research and development investments, including investments done both internally and ...

The activist investor claims Pfizer failed to capitalize on the windfall earned from its COVID-19 vaccine and, in the process, destroyed tens of billions of dollars in market value.

Starboard Value contends that Kenvue, with strong consumer health brands like Tylenol and Listerine, is underperforming its ...

Activist investor Starboard Value urged Pfizer’s (PFE) leadership to do “something different” and hold management accountable ...